Department of Pharmaceutical Sciences
University of Puerto Rico, USA
Dr. Duconge is Associate Professor in the Pharmaceutical Sciences Department at the University of Puerto Rico School of Pharmacy. He earned his PhD degree at the University of Havana, Cuba. He has teaching experience of more than 13 years in Pharmacokinetics, Biopharmaceutics and Pharmacogenomics. He completed research training in pharmacometrics at Cambridge University, UK and the State University of New York at Buffalo and in pharmacogenomics at Hartford Hospital CT. He is the author of 48 scientific publications including reviews book chapter and articles in peer reviewed journals. He has been awarded with NICHD Grant 5G11HDO46326 and Grant 5P20RR011126 to conduct pharmacogenetic studies in Puerto Ricans. He has served as a reviewer of peer reviewed journals in the area of pharmacokinetics and pharmacogenomics and is an editorial advisory board member of Current Clinical Pharmacology. He is member of the American Association of College of Pharmacy 4 times honored with the Teacher of the Year Award. He also earned the Annual National Prize of Health Sciences Cuban Public Health Services; Best Doctoral Thesis in Pharmaceutical Sciences Cuban National Council of Scientific Degrees and 3 times the Research Achievement Awards University of Havana. His biography was included in the WHO in America 2009 edition.
Current research interest and expertise is in the area of pharmacogenomics and DNA-guided personalized medicine for better understanding the genetic basis of the observed variability in the response to medications, including adverse effects and drug metabolism, in Hispanics with cardio-metabolic disorders and other health conditions with potential disparities of care. He is also focused on conducting translational research to develop novel pharmacogenetic-driven dosing algorithms in Puerto Ricans. In addition, population pharmacokinetics-pharmacodynamics (PK/PD) data analysis and modeling, pharmacokinetics of monoclonal antibodies, kinetic of drug action in disease-state and clinical trial simulation is of interest.